Abstract:Peptide loading of MHC-I molecules plays a critical role in the T cell response to infections and tumors as well as to interactions with inhibitory receptors on natural killer (NK) cells. To facilitate and optimize peptide acquisition, vertebrates have evolved specialized chaperones to stabilize MHC-I molecules during their biosynthesis and to catalyze peptide exchange favoring high affinity or optimal peptides to permit transport to the cell surface where stable peptide/MHC-I (pMHC-I) complexes are displayed and are available for interaction with T cell receptors and any of a host of inhibitory and activating receptors. Although components of the endoplasmic reticulum (ER) resident peptide loading complex (PLC) were identified some 30 years ago, the detailed biophysical parameters that govern peptide selection, binding, and surface display have recently been understood better with advances in structural methods including X-ray crystallography, cryogenic electron microscopy (cryo-EM), and computational modeling. These approaches have provided refined mechanistic illustration of the molecular events involved in the folding of the MHC-I heavy chain, its coordinate glycosylation, assembly with its light chain, β2-microglobulin (β2m), its association with the PLC, and its binding of peptides. Our current view of this important cellular process as it relates to antigen presentation to CD8+ T cells is based on many different approaches: biochemical, genetic, structural, computational, cell biological, and immunological. In this review, taking advantage of recent X-ray and cryo-EM structural evidence and molecular dynamics simulations, examined in the context of past experiments, we attempt a dispassionate evaluation of the details of peptide loading in the MHC-I pathway. By critical evaluation of several decades of investigation, we outline aspects of the peptide loading process that are well-understood and indicate those that demand further detailed investigation. Further studies should contribute not only to basic understanding, but also to applications for immunization and therapy of tumors and infections.

Endogenous Antigen Presentation of MHC Class II Epitopes through Non-Autophagic Pathways

The ins and outs of MHC class II-mediated antigen processing and presentation

Autophagy in MHC class II antigen processing

Autophagy and MHC-restricted Antigen Presentation

Redirecting Soluble Antigen for Mhc Class I Cross-Presentation During Phagocytosis

MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.

Cytosol to lysosome transport of intracellular antigens during immune surveillance

Transport of Misfolded Endoplasmic Reticulum Proteins to the Cell Surface by MHC Class II Molecules.

Regulation of protein synthesis and autophagy in activated dendritic cells: implications for antigen processing and presentation

Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation

Chaperone-mediated MHC-I peptide exchange in antigen presentation

Plasma Membrane Interactions That Determine Presentation of Antigens by Antigen-presenting Cells. (P5022)

Cutting Edge: Phagosome-associated Autophagosomes Containing Antigens and Proteasomes Drive TAP-Independent Cross-Presentation

Processing and Regulation Mechanisms within Antigen Presenting Cells: A Possibility for Therapeutic Modulation

Antigen presentation of post‐translationally modified peptides in major histocompatibility complexes

Alternate MHC I antigen presentation pathways allow CD8+ T-cell recognition and killing of cancer cells in the absence of ß2M or TAP

The Role of Tripeptidyl Peptidase Ⅱ in Endogenous Antigen Presentation by Major Histocompatibility Complex Class I Molecules

MHC cross-dressing in antigen presentation

Chaperone function in antigen presentation by MHC class I molecules-tapasin in the PLC and TAPBPR beyond

Progress on the Role of Ubiquitination and Autophagy in Protein Degradation and Antigen Presentation

Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk